Anti-Hypertensive Drugs Market Size Estimated to Reach $28.7 Billion by 2027

Anti-Hypertensive Drugs Market | IndustryARC
The serious impact on people with hypertension owing to the COVID-19 pandemic is set to drive the Anti-Hypertensive Drugs Market

Anti-Hypertensive Drugs Market size is estimated to reach $28.7 billion by 2027, growing at a CAGR of 3.7% during the forecast period 2022-2027. Antihypertensive drugs are medications that are utilized to treat hypertension (high blood pressure) There are distinct kinds of antihypertensive drugs that perform differently to reduce elevated blood pressure. Ethacrynic acid is a loop diuretic that acquired U.S. Food And Drug Administration (FDA) endorsement for extensive application in 1967. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are the most typically prescribed anti-hypertensive medicines in the U.S. The application of thiazide diuretics for the treatment of high blood pressure minimized blood pressure by 9 points in the upper number termed systolic blood pressure and 4 points in the lower number termed diastolic blood pressure. Diverse thiazide medications have analogous effects in reducing blood pressure and thiazides reduce systolic blood pressure more than other classes of antihypertensive medications. Calcium channel blocker is a medicine that reduces blood pressure and treats additional conditions like chest pain and erratic heartbeat.

The serious impact on people with hypertension owing to the COVID-19 pandemic is set to drive the Anti-Hypertensive Drugs Market. The soaring initiatives by private and government organizations and the surging awareness regarding hypertension involving the application of thiazide diuretics worldwide are set to propel the growth of the Anti-Hypertensive Drugs Market during the forecast period 2022-2027. This represents the Anti-Hypertensive Drugs Industry Outlook.

Anti-Hypertensive Drugs Market Segment Analysis – By Therapeutic Class:

The Anti-Hypertensive Drugs Market based on therapeutics class can be further segmented into Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, and Others. The Diuretics Segment held the largest market share in 2021. This growth is owing to the surging application of diuretics to minimize sodium and water in the body by activating the kidneys to discharge more sodium through the urine resulting in a reduction in blood pressure. Thiazide Diuretics are utilized to treat hypertension. The soaring efficiency, reduced cost and reduced chances of side-effects in comparison with other therapeutic classes are further propelling the growth of the Diuretics segment.

Furthermore, the Calcium Channel Blockers segment is estimated to grow with the fastest CAGR of 4.3% during the forecast period 2022-2027 owing to the soaring global demand for calcium channel blockers owing to their reduced side-effects in comparison with other antihypertensive drugs and their advantages like their positive impact on complete health and delaying the advancement of chronic renal failure.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=15692

Report Price: $ 4500 (Single User License)

Anti-Hypertensive Drugs Market Segment Analysis – By Distribution Channel:

The Anti-Hypertensive Drugs Market based on distribution channels can be further segmented into Retail Pharmacies, Hospital Pharmacies, Online Stores, and Others. The Retail Pharmacies segment held the largest market share in 2021. This growth is owing to the soaring application of retail pharmacies resulting in enhanced patient satisfaction. Antihypertensive medications like thiazide diuretics may be available in retail pharmacies. Pharmacists with access to full patient histories-inclusive of the specialists they consulted, the medicines they consumed, and more-are better able to counsel patients on safe application. Collaboration may also bring down the outpatient medicine errors, an enormous hazard when patients leap from pharmacy to pharmacy post clearance. The care team collaboration to enhance patient outcomes is thus further propelling the growth of this segment.

Furthermore, the Online segment is estimated to grow with the fastest CAGR of 4.5% during the forecast period 2022-2027 owing to the surging application of online pharmacies like PharmEasy offering antihypertensive drugs like thiazide diuretics including Chlorthalidone.

Anti-Hypertensive Drugs Market Segment Analysis – By Geography:

The Anti-Hypertensive Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Anti-Hypertensive Drugs Market) held the largest share with 35% of the overall market in 2021. The growth of this region is owing to the increasingly effortless application of antihypertensive medications like thiazide diuretics in the region. The surging population of the elderly in conjunction with their increased susceptibility to hypertension is further driving the growth of the Anti-Hypertensive Drugs Market in this region. The existence of key players like Pfizer, Inc. in the U.S. in the region is further propelling the growth of the Anti-Hypertensive Drugs Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like soaring awareness of antihypertensive medications like thiazide diuretics in the Asia-Pacific region. The proliferation in government schemes and initiatives for enhancing the healthcare sector, integrated with the surging predominance of Chronic Obstructive Pulmonary Disease (COPD) in China is further fueling the progress of the Anti-Hypertensive Drugs Market in the Asia-Pacific region.

Anti-Hypertensive Drugs Market Drivers

Surging Applications Of Thiazide Diuretics Against Hypertension Are Projected To Drive The Growth Of Anti-Hypertensive Drugs Market:There

are numerous causes of hypertension (high blood pressure) inclusive of progressive age, smoking, and obesity. Occasionally, the fundamental cause of hypertension cannot be decided, leading to a diagnosis of idiopathic hypertension. Unregulated hypertension will ultimately cause damage to the heart, kidneys, and eyes. Thiazide diuretics are principally utilized to treat hypertension (high blood pressure) and edema (swelling) brought about by water overload and some conditions connected to irregular calcium metabolism. Thiazides and thiazide-like diuretics have been in consistent use since their launch in 1958. Typically, thiazides and thiazide-like diuretics minimize the hazard of loss of life, stroke, heart attack, and heart failure owing to hypertension. Guidelines in the U.S. advocate thiazides as a first-line treatment for hypertension (JNC VIII). A systematic examination by the Cochrane Collaboration particularly advocated that low-dose thiazides be utilized as the beginning pharmacological therapy for high blood pressure. Low-dose thiazides are more efficient at treating hypertension than beta-blockers and are identical to angiotensin-converting enzyme (ACE) inhibitors. Thiazides are an advocated treatment for hypertension in Europe (ESC/ESH). Thiazides should be regarded as beginning treatment if the patient has a soaring hazard of establishing heart failure. Thiazide-type diuretics (chlorthalidone and indapamide) have been displayed to be superior in averting cardiovascular disease at a reduced cost. Suggestions are to begin them as first-line treatment for hypertension. The surging applications of thiazide diuretics against hypertension are therefore fuelling the growth of the Anti-Hypertensive Drugs Market during the forecast period 2022-2027.

Soaring Applications Of Calcium Channel Blocker Against Hypertension Are Expected To Boost The Demand Of Anti-Hypertensive Drugs Market:

As per World Health Organization, an approximated 1.28 billion mature grown-ups aged 30-79 years globally have hypertension, most (two-thirds) residing in low- and middle-income countries. A calcium channel blocker is the medication that is utilized against hypertension and chest pain. It slows the calcium motion that assists in broadening the blood vessels thereby minimizing blood pressure and making it effortless for the heart to pump the blood. The population of the elderly is increasing at an accelerated pace owing to medical progress and the curbing of incessant ailments. Calcium channel blocker has been demonstrated to be efficient in this condition in the elderly. The success relies on the technique of action, and on the physiological alterations recognized, and on the aging process itself, which involves cardiac hypertrophy, calcification of cardiac valves, and a reduction in the excitation-conduction system. Calcium channel blocker has been demonstrated to be efficient in any age group for the handling of hypertension and is safe for use in elderly patients. This medication obstructs L-type calcium channels, with the long-acting or most-recent generation dihydropyridines being the most efficient of this group. Numerous investigations, inclusive of SYST-EUR2, NORDIL, and STOP-2, have displayed the efficiency of these medications in elderly patient. The prescribing of long-acting calcium channel blocker medications in a single dose is the most suggested. The security in the application of this medication group has been established in the treatment of hypertension in elderly patient, with a level of efficiency identical to additional extensively utilized medications. These kinds of soaring applications of calcium channel blockers against hypertension are driving the growth of the Anti-Hypertensive Drugs Market during the forecast period 2022-2027.

Direct Purchase link @ https://www.industryarc.com/purchasereport.php?id=15692

Anti-Hypertensive Drugs Market Challenges

The Hazard Of Falls And/Or Fractures In The Elderly Is Hampering The Growth Of The Anti-Hypertensive Drugs Market:

Antihypertensive medications utilized to treat hypertension in the elderly may bring about and/or aggravate pre-existing orthostatic hypotension (OH) leading to poor balance, dizziness, tiredness, weakness, and even falls with consequent injury inclusive of fractures. The treatment of hypertension in the elderly needs further explanation as numerous international guidelines are inconstant in offering suggestions on optimal BP goals for both initiations of therapy and for treatment in the elderly owing to the restricted result data from randomized controlled trials (RCTs) in this population. While the guidelines concentrate on the morbidity and mortality advantages from the treatment of hypertension, it is vital to note that there are also clinical investigations that have displayed possible hazards related to the application of antihypertensive medications in hypertensive elderly patients. Elderly patients classically treated in clinical practice tend to be fragile, with diversified comorbidities and polypharmacy. These kinds of patients are frequently not included in clinical trials assessing antihypertensive treatment. Furthermore, elderly hypertensive patients are more likely than their younger equivalents to have orthostatic hypotension (OH). Consequently, elderly hypertensive patients are at a heightened hazard of falls and/or fractures succeeding antihypertensive medication introduction. Thus, handling antihypertensive treatment of the elderly may be challenging in clinical practice in terms of balancing the recognized advantages with the possible hazards of therapy. This issue is hampering the growth of the Anti-Hypertensive Drugs Market.

Anti-Hypertensive Drugs Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Hypertensive Drugs Market. Key companies of this market are:

C.H. Boehringer Sohn AG & Ko. KG
Noden Pharma
Merck & Co. Inc.
Daiichi Sankyo Company Limited
Novartis AG
Johnson & Johnson Ltd,
Ranbaxy Laboratories Limited
Sanofi SA
Pfizer, Inc.
AstraZeneca plc

Recent Developments

In November 2021, Daiichi Sankyo Company, introduced DELYTACT® (teserpaturev/G47)*1, an oncolytic virus established by the firm in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo. DELYTACT® accepted conditional and time-limited marketing endorsement in Japan as a regenerative medical product for the treatment of malignant glioma in June 2021 based on outcomes from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma*2 (a kind of malignant glioma*3) directed by Dr. Todo. For the time being, DELYTACT® will be commercially accessible only at hospitals that acted as trial sites.

In June 2021, C.H. Boehringer Sohn AG & Ko. KG and Eli Lilly & Company declared to have accepted marketing permission from the European Commission, for their incessant heart failure treatment medication, Jardiance® (Empagliflozin). The current advancement is an expansion of a positive endorsement accepted from the Committee for Medicinal Products for Human Use (CHMP). The currently endorsed Jardiance will presently be utilized by mature grownups enduring incessant heart failure and minimized ejection fraction (systolic heart failure).

In June 2021, Merck termed MSD outside the U.S. and Canada, declared that it has finished the spinoff of Organon & Co. (Organon). Merck’s objective with the spinoff was to build two patient-focused firms with an improved strategic and operational focus, enhanced agility, abridged operating models, optimized capital structures, and enhanced financial profiles. Merck trusts the transaction will convey important advantages for both Merck and Organon and develop a value for Merck shareholders.

Key Takeaways

Geographically, the North American Anti-Hypertensive Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring predominance of hypertension and ailments bringing about hypertension which may require the application of calcium channel blockers in the North American region.

Anti-Hypertensive Drugs Market growth is being driven by the increasing predominance of hypertension across the world requiring the application of calcium channel blockers and the ability of certain medications to induce hypertension in patients with additional ailments. However, the termination of patent of numerous principal medications together with side-effects related to hypertension treatment is one of the major factors hampering the growth of the Anti-Hypertensive Drugs Market.

Anti-Hypertensive Drugs Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Anti-Hypertensive Drugs Market report.

Related Reports

Hypertension Drugs Market

https://www.industryarc.com/Research/Hypertension-Drugs-Market-Research-501963

For more Lifesciences and Healthcare related reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/